Can you detail Pyramid Labs’ growth?

Growth was largely organic, driven by quality performance and word-of-mouth referrals. In 2023, Audax Private Equity acquired the company, bringing in an experienced management team and investing in expansion initiatives. This includes the launch of a high-speed fill line for pre-filled syringes, cartridges and vials—enhancing Pyramid’s ability to support large-scale commercial programs.

How is Novo Nordisk’s acquisition of Catalent reshaping the CDMO landscape?

One immediate consequence has been a reduction in available manufacturing capacity, particularly for injectables, forcing many clients to seek alternative partners.

The ripple effects of the Catalent acquisition and the surging demand for GLP-1 drugs are reshaping the market. Companies need stable, reliable CDMO partners, and we are strategically positioned to fill that gap.

How is Pyramid Labs adapting to industry trends and emerging drug modalities?

The pharmaceutical landscape is rapidly evolving, with biologics, peptides and oligonucleotides gaining prominence. While monoclonal antibodies have long dominated the field, more complex modalities such as bispecific antibodies and fusion proteins are becoming increasingly common. The success of GLP-1 receptor agonists has fueled further investment in peptides, solidifying their place as a viable drug class.

Beyond technical capabilities, the nature of CDMO-client relationships is changing. Pharmaceutical companies are moving away from transactional engagements and seeking long-term strategic partnerships. Alignment on business strategy, culture and operational philosophy is now a critical factor in vendor selection.

How is Pyramid Labs expanding capabilities in device assembly and testing?

Pyramid Labs is launching device assembly and testing capabilities in 2025. The company already provides labeling and packaging services and will now support the assembly of auto-injectors and other drug delivery devices.

The integration of device assembly and testing aligns with industry trends toward self-administration and combination products. By offering these services alongside our existing fill-finish and packaging capabilities, we are ensuring clients have a seamless path from drug manufacturing to patient-ready products.

How is the shift toward self-administration driving changes in fill-finish demand and capabilities?

A major trend shaping the industry is the increasing emphasis on patient-centric drug delivery. Self-administration is becoming the norm, driving demand for pre-filled syringes and autoinjectors. However, higher drug concentrations and increased viscosity present unique formulation and manufacturing challenges.

Moving from a 20 mg/mL antibody solution in a vial to a 200–250 mg/mL concentration for a pre-filled syringe requires advanced formulation expertise to maintain stability. This complexity extends to the fill-finish process, necessitating specialized equipment and knowledge.

To address these needs, Pyramid Labs has expanded its capabilities in pre-filled syringes, supporting both clinical and commercial production.

What has been the focus of the firm’s R&D efforts?

Pyramid Labs is making significant investments in product stability and advanced formulation development. A key area of focus is the interface between drug manufacturing, fill-finish processing, and medical device assembly and the unique challenges associated with pre-filled syringes—such as interactions with siliconized glass barrels—require specialized analytical expertise to mitigate stability risks.

We are investing heavily in technology and infrastructure to address these challenges. This includes strengthening our development capabilities to support high-concentration formulations and combination product integration.

Regulatory expectations for combination products continue to evolve, further underscoring the need for expertise in quality control and operational execution.

What are Pyramid Labs’ goals for 2025 and beyond?

As Pyramid Labs enters 2025, the company is focused on executing its strategic growth plan. The launch of its high-speed fill line in Q3 will expand its ability to meet the increasing demand for injectable drug products. Additionally, the company is onboarding new programs, particularly for late-stage clinical and commercial production.

Our goal is to be the CDMO of choice for clients seeking agility, technical expertise and long-term partnership. With strong backing from Audax and a clear strategic vision, we are well-positioned to drive continued growth and innovation in the years ahead.

As the industry continues to evolve, Pyramid Labs stands out as a stable, reliable and forward-thinking partner in an increasingly complex pharmaceutical landscape.